JP Morgan Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $20
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $20.
JP Morgan initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $20.